Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Study sponsor: Allarity Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-04-01Actual
Enrollment · participants20Actual
Source updated2025-01-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.